Derm Dispatch: Rethinking Mastocytosis in Clinical Practice

In a recent episode of Derm Dispatch, host Renata Block, DMSc, MMS, PA-C, sat down with Lauren Madigan, MD, associate professor of dermatology at University of Utah Health and cutaneous mastocytosis expert at the Huntsman Cancer Institute, to review practical updates in the evaluation and management of mastocytosis in the skin. Their discussion highlights both the heterogeneity of the disease and the importance of age-specific risk stratification.

Defining the Spectrum

Cutaneous mastocytosis refers to an infiltration and proliferation of clonal mast cells in the skin. Clinically, it encompasses both disease limited to the skin and cutaneous manifestations of systemic mastocytosis. Madigan emphasized 3 classic cutaneous subtypes:

1. Solitary (or few) mastocytomas, typically presenting in infancy or early childhood and often remitting by adolescence.
2. Diffuse cutaneous mastocytosis (DCM), also usually pediatric in onset, characterized by widespread skin thickening, hyperpigmentation, and significant mediator-related symptoms.
3. Maculopapular cutaneous mastocytosis (MPCM), the most heterogeneous category, historically termed urticaria pigmentosa.

An international consensus further subdivided MPCM into polymorphic and monomorphic variants. This distinction carries clinical weight: polymorphic lesions—variable in size and distribution—are more common in children and are typically skin-limited. Monomorphic lesions, often smaller and more uniform, are more characteristic of adult-onset disease and raise concern for systemic involvement.

Children Are Not Small Adults

One of the most clinically relevant themes of the discussion was the stark contrast between pediatric and adult disease. In children, mastocytosis is far more likely to remain confined to the skin and follow a benign, often self-limited course. Even in diffuse disease, many cases improve by adolescence.

Monitoring in pediatric patients focuses on clinical follow-up: serial skin exams, abdominal examination for hepatosplenomegaly, and serum tryptase levels when indicated. While progression to systemic disease is possible, it is uncommon—particularly in polymorphic MPCM.

In adults, however, the calculus changes. Adult-onset monomorphic MPCM is frequently associated with systemic mastocytosis. In these patients, identifying an activating KIT mutation (most commonly D816V) has diagnostic and prognostic implications and often guides further hematologic evaluation.

Mediator Symptoms and Clinical Burden

Across age groups, mast cell mediator release—flushing, pruritus, abdominal pain, hypotension, and anaphylaxis—can significantly impact quality of life. Diffuse cutaneous mastocytosis in children may be particularly symptomatic. Treatment remains largely symptom-directed, including H1 and H2 antihistamines, leukotriene modifiers, and trigger avoidance. Systemic therapies are reserved for select cases with advanced or refractory disease.

An Algorithmic Approach

A key takeaway from the episode is the value of structured evaluation. Distinguishing polymorphic from monomorphic disease, integrating age at onset, assessing for systemic signs, and using targeted laboratory testing allows clinicians to avoid both under- and over-investigation.

For dermatology clinicians, the message is clear: morphology and age matter. Recognizing patterns not only reassures families of young patients but also ensures timely referral and workup in adults at higher risk for systemic disease.